Hoffmann-La Roche

ICO icon

Hoffmann-La Roche

Status

Ongoing

Description

Founded in 1896 by Fritz Hoffmann-La Roche, the company was early on known for producing various vitamin preparations and derivatives. In 1934, it became the first company to mass-produce synthetic vitamin C, under the brand name Redoxon. In 1957 it introduced the class of tranquilizers known as benzodiazepines (with Valium and Rohypnol being the best known members). It manufactures and sells several cancer drugs and is a leader in this field. In 1956, the first antidepressant, iproniazid, was accidentally created during an experiment while synthesizing isoniazid. Originally, it had been intended to create a more efficient drug at combatting Tuberculosis. Iproniazid, however, revealed to have its own benefits; some people felt it made them feel happier. It was withdrawn from the market in the early 1960s due to toxic side-effects.

Starting date

March 18, 2020

Ending date

August 9, 2021

Project Details
ICO Details
Team

F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding companyRoche Holding AG, has bearer shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.

The company controls the American biotechnology company Genentech, which is a wholly owned affiliate, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States-based Ventana. Roche’s revenues during fiscal year 2018 were 56.85 billion Swiss francs,[4] or approximately US$57 billion. Roche is the second-largest pharmaceutical company worldwide.[5] Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares. Roche is one of the few companies increasing their dividend every year, for 2018 as the 32nd consecutive year.[4] F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[6]

Raised

$19,500,000

Softcap

$25,000,000

Hardcap

$40,000,000

Core Team
Steven Gonzalez
Founder & CEO
Reginald Wilson
Chief Operational Officer
Walter Perry
Lead Software Developer
Advisory Team
Anne Magee
Michael Rivera
Herman John
Carol Gregory
You don't have permission to register